Martínez Rosa, Gutierrez-Nogués Ángel, Fernández-Ramos Concepción, Velayos Teresa, Vela Amaia, Navas María-Ángeles, Castaño Luis
Endocrinology and Diabetes Research Group, BioCruces Health Research Institute, UPV-EHU, CIBERDEM, CIBERER, Cruces University Hospital, Barakaldo, Spain.
Department of Biochemistry and Molecular Biology III, Faculty of Medicine, CIBERDEM and Hospital Clínico San Carlos Health Research Institute, Complutense University of Madrid, Madrid, Spain.
Clin Endocrinol (Oxf). 2017 Jun;86(6):778-783. doi: 10.1111/cen.13318. Epub 2017 Mar 27.
Mutations in the GCK gene lead to different forms of glucokinase (GCK)-disease, activating mutations cause hyperinsulinaemic hypoglycaemia while inactivating mutations cause monogenic diabetes. Hyperinsulinism (HI) is a heterogeneous condition with a significant genetic component. The major causes are channelopathies, the other forms are rare and being caused by mutations in genes such as GCK.
To describe the clinical and genetic presentation of four families with activating GCK mutations, and to explore the pathogenicity of the novel mutation identified through functional studies.
Four cases of HI with mutations in GCK were identified. These include one novel mutation (p.Trp99Cys). Functional analysis of the purified mutant fusion protein glutathione-S-transferase (GST)-GCK-p.Trp99Cys demonstrated that p.Trp99Cys is an activating mutation as it induces a higher affinity for glucose and increases the relative activity index more than 11 times. Moreover, the thermal stability of the mutant protein was similar to that of its wild type. All patients were responsive to diazoxide treatment. One of the mutations arose de novo, and two were dominantly inherited, although only one of them from an HI affected parent. The age of presentation in our cases varied widely from the neonatal period to adulthood.
The clinical phenotype of the GCK activating mutation carriers was heterogeneous, the severity of symptoms and age at presentation varied markedly between affected individuals, even within the same family. The novel activating GCK mutation (p.Trp99Cys) has a strong activating effect in vitro although it has been identified in one case of a milder and late-onset form of HI.
GCK基因突变会导致不同形式的葡萄糖激酶(GCK)疾病,激活突变会引起高胰岛素血症性低血糖,而失活突变会导致单基因糖尿病。高胰岛素血症(HI)是一种具有重要遗传成分的异质性疾病。主要病因是离子通道病,其他形式较为罕见,由GCK等基因的突变引起。
描述4个携带GCK激活突变家族的临床和基因表现,并通过功能研究探索所鉴定新突变的致病性。
鉴定出4例GCK基因突变的HI病例。其中包括1个新突变(p.Trp99Cys)。对纯化的突变融合蛋白谷胱甘肽-S-转移酶(GST)-GCK-p.Trp99Cys进行功能分析表明,p.Trp99Cys是一个激活突变,因为它诱导对葡萄糖具有更高的亲和力,并使相对活性指数增加超过11倍。此外,突变蛋白的热稳定性与其野生型相似。所有患者对二氮嗪治疗均有反应。其中1个突变是新发的,2个是显性遗传,尽管其中只有1个来自HI受累父母。我们病例的发病年龄从新生儿期到成年期差异很大。
GCK激活突变携带者的临床表型是异质性的,症状严重程度和发病年龄在受影响个体之间差异明显,即使在同一家族中也是如此。新的GCK激活突变(p.Trp99Cys)在体外具有很强的激活作用,尽管它是在1例症状较轻且发病较晚形式的HI中发现的。